Roche agrees to acquire Santaris Pharma for $450m
As part of the deal, Roche will make an upfront cash payment of $250m to Santaris shareholders and make additional contingent payments of up to $200m based on
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.
The deal provides toxicity and efficacy studies of cannabinoid formulations carried out in animal models for neurobehavioral diseases including sleep disorders. The company said that the first formulation